Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00736541 · ClinicalTrials.gov registry record · NA
N-acetylcysteine in Liver Transplantation
A NA study of End Stage Liver Failure, sponsored by Ibtesam Hilmi.
- Completed
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT00736541: Completed NA study of End Stage Liver Failure, sponsored by Ibtesam Hilmi.
NCT00736541 is a NA study of End Stage Liver Failure that has completed, run by Ibtesam Hilmi. The registered enrollment target is 100 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00736541, a NA study of End Stage Liver Failure, has completed, sponsored by Ibtesam Hilmi.
- COMPLETED
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
N-acetylcysteine (NAC) is used to treat Tylenol toxicity. NAC is a rich source of the sulfhydryl group (SH) which is important for replenishing the body's glutathione stores. Glutathione acts as a free radical scavenger, to decrease the damage that would be caused by those toxic radicals. Patients who undergo orthotopic liver transplantation (OLT) have a high incidence of post-operative renal dysfunction. The most common etiology of post-operative renal dysfunction is related to high levels of toxic free radicals. Free radicals may contribute to primary liver graft failure or delayed liver graft function. Specific Aims \& Objectives: The primary objective of this study is to evaluate the efficacy of NAC in improving liver graft performance and lowering the incidence of post-operative renal dysfunction. The secondary objectives are to investigate the effect of NAC on endogenous glutathione body stores and its effect on FK506 induced toxicity.
Conditions Studied
Interventions
- DRUG N-acetylcysteine
Study Locations (1)
Pennsylvania
- Unversity of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2004-07 |
| Est. Completion | 2008-01 |
| Phase | NA |
What the finished NCT00736541 record still lists
NCT00736541 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 1 condition, with End Stage Liver Failure appearing as the primary indexed condition, and to 1 intervention - of which N-acetylcysteine is the first listed.
NCT00736541 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00736541 about?
NCT00736541 is a clinical study titled "N-acetylcysteine in Liver Transplantation". N-acetylcysteine (NAC) is used to treat Tylenol toxicity. NAC is a rich source of the sulfhydryl group (SH) which is important for replenishing the body's glutathione stores. Glutathione acts as a free radical scavenger, to decrease the damage that would be caused by those toxic radicals. Patients w...
What is the current status of trial NCT00736541?
This trial is currently completed. It is a NA study. The enrollment target is 100 participants. The study started on 2004-07. Estimated completion is 2008-01.
What conditions does trial NCT00736541 study?
This clinical trial studies the following conditions: End Stage Liver Failure.
What interventions are being tested in trial NCT00736541?
The interventions under investigation include: N-acetylcysteine (DRUG).
Who is sponsoring clinical trial NCT00736541?
This trial is sponsored by Ibtesam Hilmi, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00736541 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00736541's enrollment target sits among peer trials
100 840th of 2000 higher than 1,081 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia